News

Article

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Author(s):

Fact checked by:

Key Takeaways

  • FDA approved subcutaneous Opdivo for solid tumors, excluding dual immunotherapy with Yervoy, enhancing treatment convenience and accessibility.
  • CHECKMATE-67T trial showed subcutaneous Opdivo's non-inferiority in drug exposure compared to the IV formulation.
SHOW MORE

Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

Dr. Eric K. Singhi, an assistant professor in both the Department of General Oncology and the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, Texas, recently sat down for an interview with CURE®.

In the interview, he discussed the Dec. 27, 2024, Food and Drug Administration (FDA) approval of subcutaneous Opdivo and Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors. He goes on to discuss the significance of the regulatory approval, as well as the trial data that led the approval.

Glossary:

Intravenous (IV): when a needle is inserted into a vein to administer fluids or medications directly into the bloodstream.

Overall response rate: how many patients experienced a significant shrinkage or disappearance of their tumors after treatment.

Subcutaneous: beneath the skin.

To read our full interview with Singhi, check it out here!

Transcript:

As of Dec. 27, 2024, the FDA approved subcutaneous — or under the skin — Opdivo for patients with a wide range of solid tumors. This includes renal cell carcinoma [RCC], melanoma, non-small cell lung cancer and others. The new approval applies to almost all existing solid tumor indications for the IV [intravenous] formulation, except it is not allowed for use in combination with what we call dual immunotherapy or CTLA4 inhibition with Yervoy [ipilimumab].

This approval brings a subcutaneously administered PD1 inhibitor to the market, and it could be significant for patients because it provides a new, more convenient option for treatment. This allows patients to potentially receive treatment closer to home with less time spent at treatment facilities, and it can improve both convenience and accessibility.

This approval was based on data from the phase 3 CHECKMATE-67T trial, and that included 495 patients with advanced or metastatic clear cell RCC, which is a type of kidney cancer. Importantly, these patients had to have received no more than two prior lines of treatment against their cancer. The trial compared subcutaneous — under the skin — Opdivo with the IV formulation of Opdivo, which is that traditional form of immunotherapy. What they looked at was a primary focus on assessing drug pharmacokinetics. Specifically, they looked at exposure through the time average concentration and minimum concentration at steady state.

What they saw from the results perspective was that the subcutaneous, under-the-skin Opdivo was non-inferior to the IV version, so it indicated comparable levels of drug exposure. What they also saw was that the overall response rate, meaning the percentage of patients that respond to treatment, was actually higher for subcutaneous nivolumab, at 24% compared with 18% for the IV formulation. This really supports the efficacy of the subcutaneous version.

Safety profiles were also the same, or very similar between the two arms. In the subcutaneous, under-the-skin arm, the most common adverse effects were reported in at least 10% of patients, and they included fatigue, musculoskeletal pain, pruritus or intense itching, rash and cough.

Transcript was edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Related Content